By Gilang Cahya 
Researchers at the Francis Crick Institute, in a significant collaboration with Revolution Medicines, have unveiled promising preclinical findings in mice, demonstrating that a novel combination therapy can effectively enable immunotherapies to target and combat lung tumors that were previously unresponsive. This breakthrough, published today in the esteemed journal Nature Communications, suggests that a multi-pronged attack on cancer cells, simultaneously addressing different vulnerabilities, could dramatically enhance treatment efficacy. The research team’s meticulous work offers a potential paradigm shift in treating lung cancers, particularly those that have historically evaded current therapeutic strategies.
The Challenge of Immunotherapy Resistance in Lung Cancer
Lung cancer remains a leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. While immunotherapies, such as immune checkpoint inhibitors (ICIs), have revolutionized cancer treatment by harnessing the patient’s own immune system to fight tumors, a significant proportion of patients do not respond to these therapies. This lack of response is often attributed to the tumor microenvironment, which can be "immune cold," meaning it lacks the necessary immune cells and signals to initiate an effective anti-tumor response. These "immune cold" tumors are characterized by a dense stroma, a lack of tumor-infiltrating lymphocytes, and the presence of immunosuppressive cells and factors that effectively shield them from immune surveillance.
The KRAS gene is one of the most frequently mutated oncogenes in human cancers, particularly in lung adenocarcinoma, a subtype of NSCLC. Mutations in KRAS, especially the G12C variant, are drivers of tumor growth and proliferation. While inhibitors targeting KRAS G12C have been developed and are showing promise, resistance mechanisms often emerge, limiting their long-term effectiveness. Similarly, the SHP2 protein plays a crucial role in various signaling pathways that promote cell growth and survival, and its dysregulation is implicated in cancer progression. Blocking SHP2 has emerged as another therapeutic avenue, with compounds designed to inhibit its activity.
A Strategic Triplet Combination: Unlocking Immune Potential
The Crick Institute and Revolution Medicines team designed a sophisticated treatment strategy that addresses these challenges by combining three distinct therapeutic agents. This approach aims to create a synergistic effect, where the combined impact of the drugs is greater than the sum of their individual effects.
The core of this innovative strategy involves the simultaneous blockade of key molecular pathways within the tumor and its surrounding microenvironment. The researchers utilized a newly identified inhibitor targeting the KRAS G12C mutation, a critical driver in many lung cancers. This was combined with a compound designed to block the SHP2 protein. SHP2 is a tyrosine phosphatase that plays a complex role in cancer, often acting as an oncogene by promoting cell proliferation and survival. Crucially, SHP2 also plays a role in regulating immune responses within the tumor microenvironment. By inhibiting SHP2, the researchers aimed to disrupt cancer cell signaling and, importantly, to potentially "warm up" the tumor by making it more susceptible to immune attack.
The third component of this potent cocktail is an immune checkpoint inhibitor (ICI). ICIs work by releasing the brakes on the immune system, allowing T cells to recognize and attack cancer cells. However, their effectiveness is often hampered in tumors that are not pre-sensitized to immune attack. By combining the KRAS G12C inhibitor and the SHP2 inhibitor, the researchers hypothesized that they could create an environment where the ICI could then effectively engage the immune system.
Preclinical Success: Shrinking Tumors and Eradicating Recurrence
The results from the mouse models were compelling. In mice with functional immune systems, the triplet combination therapy demonstrated a remarkable ability to shrink tumors. In a significant subset of these animals, the tumors were completely eradicated. Furthermore, these mice exhibited a heightened resistance to the recurrence of lung cancer, suggesting that the treatment not only eliminated existing tumors but also established a form of immunological memory that could prevent future growth.
This success was not limited to tumors that were already somewhat responsive to immune intervention. Even in mice with "immune cold" tumors – those notoriously resistant to immunotherapy – the combination therapy proved effective. The researchers observed that the triplet regimen was able to sensitize these previously recalcitrant tumors to the effects of the immune checkpoint inhibitor. This suggests that the KRAS and SHP2 inhibition effectively reprogrammed the tumor microenvironment, creating an opening for the immune system to infiltrate and destroy cancer cells.
The proposed mechanism behind this success is that the targeted compounds create a "window of opportunity." By inhibiting KRAS and SHP2, the cancer cells are weakened, and the immunosuppressive signals within the tumor microenvironment are disrupted. This disruption allows the immune checkpoint inhibitor to become more effective, enabling the body’s natural defenses – specifically cytotoxic T lymphocytes – to recognize and eliminate the tumor cells.
Expert Commentary and Future Directions
Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick and co-senior author of the study, emphasized the significance of overcoming resistance. "Blocking genes like KRAS in lung cancer has led to some exciting new developments, but we still see problems with resistance," he stated. "We’ve now been able to report partial or complete eradication of tumours in mice by combining KRAS and SHP2 inhibitors with immunotherapy. We also showed that this combination therapy allows ‘immune cold’ tumours to respond to the body’s own defences."
Panos Anastasiou, a PhD student in the Oncogene Biology Laboratory at the Crick and the study’s first author, highlighted the broader implications of the findings. "Our work stresses the importance of targeting tumours from all angles, especially ones that don’t respond easily to treatment," Anastasiou remarked. "It will be critical to see if the combination of inhibitors works in the same way in humans."
The research was supported by a collaborative research agreement with Revolution Medicines, underscoring the strong partnership between academic institutions and industry in driving translational research. Additional funding from the European Union and the Wellcome Trust further facilitated this groundbreaking work.
Broader Implications and Next Steps
The successful preclinical outcomes of this triplet combination therapy carry profound implications for the future of lung cancer treatment. If these results can be replicated in human clinical trials, it could offer a new lifeline to patients with advanced or resistant lung cancers who currently have limited treatment options. The ability to overcome immune evasion in "immune cold" tumors is particularly noteworthy, as this represents a major hurdle in maximizing the benefits of immunotherapy for a wider patient population.
The research team is keenly aware of the challenges ahead. The complexity of combining multiple therapeutic agents necessitates careful consideration of potential side effects. Further research will be essential to thoroughly understand and effectively manage any adverse events associated with this combination.
The next logical step in this research trajectory is to translate these promising preclinical findings into human clinical trials. Evaluating the safety and efficacy of this triplet therapy in patients with lung cancer will be a crucial undertaking. This will involve meticulous planning, rigorous study design, and close collaboration between researchers, clinicians, and regulatory bodies.
Moreover, ongoing research will likely focus on refining the treatment regimen, potentially exploring different dosing schedules, combinations of specific agents, and patient selection criteria to optimize outcomes. Understanding the detailed molecular mechanisms by which this combination therapy sensitizes tumors and engages the immune system will also be critical for further therapeutic development and personalized medicine approaches.
The journey from laboratory discovery to widespread clinical application is often long and arduous, but the findings from the Francis Crick Institute and Revolution Medicines represent a significant stride forward. This innovative approach to tackling the complexities of lung cancer, particularly its resistance to existing therapies, offers a beacon of hope for patients and a testament to the power of collaborative scientific endeavor. The potential to unlock the full power of the immune system against even the most challenging forms of cancer is a goal that this research brings closer to reality.
